Compare
Theriva Biologics, Inc. vs Jaguar Health, Inc. vs Cue Biopharma, Inc. vs BioXcel Therapeutics, Inc.
| Latest fiscal year | Theriva Biologics, Inc. TOVX | Jaguar Health, Inc. JAGX | Cue Biopharma, Inc. CUE | BioXcel Therapeutics, Inc. BTAIQ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $11.51M | $27.47M | $642.0K |
| Revenue growth (YoY) | n/a | -1.5% | +195.7% | -71.7% |
| Gross margin | n/a | 67.2% (computed) | n/a | 74.5% (computed) |
| Operating margin | n/a | -398.8% | -96.7% | n/m |
| Net margin | n/a | -465.4% | -96.9% | n/m |
| Net income | -$23.74M | -$53.58M | -$26.60M | -$69.90M |
| EPS (Diluted) | -$2.08 | -$22.97 | -$0.28 | -$5.73 |
| Operating cash flow | -$16.67M | -$23.69M | -$21.69M | -$57.62M |
| Free cash flow | -$16.70M | n/a | -$21.86M | -$57.62M |
| Cash & equivalents | $13.06M | $968.0K | $27.14M | $28.41M |
| Total assets | $38.24M | $38.32M | $42.21M | $44.92M |
| Total liabilities | $22.86M | $57.01M | $15.78M | $140.38M |
| Shareholders' equity | $15.38M | -$18.69M | $26.43M | -$95.46M |
| Return on year-end equity | -154.3% | n/a | -100.6% | n/a |
| Shares outstanding | 35.69M | n/a | 96.62M | 22.33M |
Revenue, most recent five fiscal years
| Fiscal year | Theriva Biologics, Inc. | Jaguar Health, Inc. | Cue Biopharma, Inc. | BioXcel Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2011-12-31 | $11.51M Ended 2025-12-31 | $27.47M Ended 2025-12-31 | $642.0K Ended 2025-12-31 |
| 1 year earlier | $2.61M Ended 2010-12-31 | $11.69M Ended 2024-12-31 | $9.29M Ended 2024-12-31 | $2.27M Ended 2024-12-31 |
| 2 years earlier | n/a | $9.76M Ended 2023-12-31 | $5.49M Ended 2023-12-31 | $1.38M Ended 2023-12-31 |
| 3 years earlier | n/a | $11.96M Ended 2022-12-31 | $1.25M Ended 2022-12-31 | $375.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $4.33M Ended 2021-12-31 | $14.94M Ended 2021-12-31 | n/a |